DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced that chief medical officer Dr. Omar Manejwala will participate in the upcoming annual American Health Insurance Plans National Conference on Medicare, Medicaid and Dual Eligibles. The conference is slated for Sept. 21–24, with Manejwala’s presentation scheduled for Sept. 22 at 12:45 p.m. EST. Titled “Digital Therapeutics in Medicaid: Unique Requirements for Unique Populations,” Manejwala’s presentation will provide insight and information on the use of innovative digital solutions in historically underserved populations. The event is designed to gather health insurance executives, government officials, health policy professionals and industry thought leaders and provide a forum for timely discussion about any issues related to Medicare and Medicaid. “The explosive growth of digital health during the pandemic served to expose and widen existing health technology disparities between commercial and Medicaid populations,” said DarioHealth chief medical officer Dr. Omar Manejwala in the press release. “Real progress requires that we challenge biases that exist today and learn how to tailor solutions to unique Medicaid requirements and leverage emerging technologies to deliver an experience that our most vulnerable populations deserve.”
To register for the conference, visit https://ibn.fm/BPLM9
To view the full press release, visit https://ibn.fm/Ui6PB
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology, and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.